ClearNote Health

Join Us at #TRICON San Diego!??? ? Our team will be out in full force at the Precision Med TRI-CON Conference, March 11-13 - come and visit us at booth #3. ? Discover how our Virtuoso Epigenomics Platform is empowering more efficient oncology drug discovery and development by leveraging 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma. ? ????Plus, don't miss the talk from our Chief Scientific Officer, Samuel Levy: Title:?Epigenomic Liquid Biopsy Tools for Individualized Signals of Therapy Response When: Tuesday, March 11, 2025, 2:25 – 2:55 PM Track: Liquid Biopsy ? Reach out to schedule a meeting: [email protected] ? #LiquidBiopsy #Cancer #Epigenomics #Oncology

?? Press Release: ClearNote Health today announced that the New York State Department of Health (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) has approved its Avantect? Pancreatic Cancer Test. With this approval, clinicians in New York State can now order this highly sensitive blood test, which is designed to detect the biological signals of pancreatic cancer in its earliest stages for patients with known risk factors. “New York State is well known for its rigorous, patient-focused quality standards for laboratory-developed tests. This approval is another critical milestone for ClearNote Health, further validating our ongoing commitment to excellence in our tests and in our clinical laboratory services,” said Dave Mullarkey, CEO at ClearNote Health. ?? Read the full press release here: https://lnkd.in/dcbybtiu #earlycancerdetection #pancreaticcancer

ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, and Senior Scientist-Translational Research, Ceyda Coruh, are attending the 9th Liquid Biopsy for Precision Oncology Summit February 18-20, San Diego. Connect to learn more about ClearNote Health's Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient oncology drug discovery and development. #drugdiscovery #drugdevelopment #oncology #cfDNA #liquidbiopsy #CDx

ClearNote Health's VP Translational Research & Head of Biopharma Development, Gulfem D. Guler, is attending the American Society of Clinical Oncology (ASCO) #GU25 Symposium, February 13-15, San Francisco. Connect with Gulfem to learn more about ClearNote Health's Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering more efficient oncology drug discovery and development. #drugdiscovery #drugdevelopment #oncology #cfDNA #liquidbiopsy

????Celebrating International Day of Women and Girls in Science!??????? ? Today, we recognize the incredible contributions of women and girls in STEM fields and celebrate those who continue to break barriers, drive innovation, and inspire future generations.???? ? Tag a woman in STEM who inspires you or share a favorite achievement by women in science! #WomenInScience #STEM #DiversityInSTEM

We are delighted to announce the signing of a strategic commercialization services agreement with M42 Health at Arab Health Exhibition 2025.? ? This collaboration marks a significant step in advancing our mission to provide early #pancreaticcancer detection with the Avantect test - a simple, cell-free DNA blood test designed to enable earlier diagnosis, improving treatment opportunities and survival rates. While at Arab Health 2025 our CEO, Dave Mullarkey, was also honored to join a?panel discussion with expert representatives from the Department of Health Abu Dhabi and Cleveland Clinic Abu Dhabi to discuss using #liquidbiopsy as a population health screening tool. ? Dave Mullarkey comments: ''It is paramount to?test?the patient populations who are at high risk of cancer, when early detection might make all the difference. By combining advanced epigenomic and genomic science as well as machine learning to detect the presence or absence of an abnormal signal in the blood - Avantect will help improve treatment outcomes and supports wider healthcare innovation in the UAE.'' ? Thank you to our partners at M42 Health for joining us in this mission,?and it is our privilege to partner with such a progressive health care organization.

At?ClearNote, we have been dedicated to advancing blood-based early cancer detection since our inception. Our technology platform offers an unprecedented understanding of cancer development, enabling earlier detection to foster life-saving treatment - all from a simple blood draw. Cancer?is a disease of the genome that misregulates normal cellular development. The ClearNote Health approach to detecting cancer early is anchored in epigenomics by tracking unique patterns of gene modulation in cancer cells and the body's?response to it. ? Our platform harnesses target enrichment of 5-hydroxymethylcytosine (5hmC) in DNA, whole genome sequencing and machine learning algorithms to enable the identification of early cancer signals, all from cell-free DNA isolated from?a blood sample . ? ??We welcome Oracle CEO Larry Ellison’s spotlight on AI’s transformative potential in blood based early cancer detection through?Project Stargate. AI’s unmatched ability to process complex datasets quickly and precisely is poised to drive even greater breakthroughs in early diagnosis, further enhancing biomarker identification through personalized cancer signatures?and saving lives. ? This welcome focus reinforces our mission and motivates us to continue pushing the boundaries of cancer detection. ?? Learn more about our technology at: https://lnkd.in/eVE68cER

Our team will be attending the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium?from January 23-25, in San Francisco. ???Don’t miss the poster presentation by our partner,?Christopher Maher,?from Washington University: Title:?5-hydroxymethylcytosine as a liquid biopsy biomarker in colorectal cancer Session: Poster Session C: Cancers of the Colon, Rectum, and Anus Track: Colorectal Cancer, Anal Cancer ???Read the abstract here:?https://lnkd.in/dCAjGfYy Alternatively, connect with?Ceyda Coruh, PhD, Senior Scientist – Translational Research, or?Gulfem D. Guler Guler, VP Translational Research & Head of Biopharma Development, to learn more about our Virtuoso Epigenomics Platform. Virtuoso leverages 5hmC epigenomic profiling to uncover active cancer biology patterns from cfDNA in plasma, empowering oncology drug discovery and development. ? We look forward to seeing you there! #epigenomics #earlycancerdetection

Our CEO, Dave Mullarkey, is attending the J.P. Morgan Healthcare Conference. Reach out to schedule a meeting and learn how ClearNote Health is improving early detection for some of the deadliest cancers. #JPMorgan #HealthCare #CancerDetection

Today, the National Cancer Institute (NCI) announced it has selected two assays to be included in the Vanguard Study on multi-cancer detection (MCD) tests. The two assays selected are Avantect? Multi-Cancer Detection Test by ClearNote Health, and Shield? Multi-Cancer Detection Test by Guardant Health.?The Vanguard Study will be conducted by the NCI-supported Cancer Screening Research Network (CSRN) to address the feasibility of using #MCD tests in future randomized controlled trials. Read more about the announcement: https://lnkd.in/eVFbMrmT Fred Hutch